A total of 73 serum specimens at the peak of IL-6 were retrospectively collected from 119 patients, and 43 of the samples were used as a training cohort to screen prognosis-related cytokines, including 12 B-ALL specimens and 31 B-NHL specimens. This evidence concerns the gene IL6 and non-Hodgkin lymphoma.